Intercell

Merck & Co. and Intercell AG terminated a clinical trial of the V710 vaccine for Staphylococcus aureus infection over safety concerns at the recommendation of an independent data-monitoring committee.

Merck Ends Vaccine Study Over Safety Concerns Melodie Warner 2011

Shares of Austrian vaccine-biotechnology company Intercell tumbled more than 22% in Vienna after the company and Merck , of the U.S., said they have terminated a trial of an investigational vaccine for the prevention of Staphylococcus aureus infection because of safety concerns.

European Stocks Slump Barbara Kollmeyer 2011

Shares of Austrian vaccine-biotechnology company Intercell tumbled more than 22% in Vienna after the company and Merck , of the U.S., said they have terminated a trial of an investigational vaccine for the prevention of Staphylococcus aureus infection because of safety concerns.

European Stocks Slump Barbara Kollmeyer 2011

Merck & Co. and Intercell AG terminated a clinical trial of the V710 vaccine for Staphylococcus aureus infection over safety concerns at the recommendation of an independent data-monitoring committee.

Merck Ends Vaccine Study Over Safety Concerns Melodie Warner 2011

Only a few vaccine players will remain to be rolled up — most importantly the vaccine business of the Australian company CSL, and possibly Denmark's Bavarian Nordic and Austria's Intercell.

Post-Postbank, Deutsche still must raise returns 2010

Also today, Merck and Intercell said that they have suspended a Phase 2 and 3 trial of an investigational vaccine for a staphylococcus aureus vaccine.

Biogen May Be Back In Business With MS Drug 2011

Iomai soared 3.42, more than doubling, to 6.34 after Austrian biotech Intercell late Monday said it agreed to acquire Iomai, a Gathersburg, Md., biopharmaceutical company, for $189 million, or $6.60 a share.

Lufkin, Tetra, Swift 2008

Intercell and Merck & Co. are jointly developing another genomically derived vaccine for staph infections.

From gene maps to drugs 2007

Also today, Merck and Intercell said that they have suspended a Phase 2 and 3 trial of an investigational vaccine for a staphylococcus aureus vaccine.

Forbes.com: News MarketNewsVideo.com 2011

Intercell AG rose 2.4 percent to 6.10 euros after the Austrian biotechnology company cut its first quarter net loss by 23.4 percent to 11.3 million euros.

BusinessWeek.com -- Top News 2011